arrow
D

David Bender

University of Iowa
H指数:33
被引数:3,735

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
2024-09-280
OAAI
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

NRG-GY012: 随机2期研究比较奥拉帕尼、西地尼布以及西地尼布/奥拉帕尼联合治疗复发性、持续性或转移性子宫内膜癌患者

CANCER
IF5.1
2023-12-214
PRE
Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
2023-10-013
PRE
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
2019-02-0135
OAAI
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability
2013-03-01104
OAAI